Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02567032 · ClinicalTrials.gov registry record · Early Phase 1
Adult Study Oxytocin - Behavioral
A Early Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 324
- Enrollment target
NCT02567032 is a Early Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 324 participants.
The verdict
NCT02567032, a Early Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 324 participants
- Enrollment target
Study Summary
In this study, investigators will examine the behavioral effects and neurophysiological mechanisms of the pro-social neuropeptide oxytocin in patients with recent-onset schizophrenia and other psychotic disorders. Such research is a necessary first step towards identifying whether intranasal oxytocin administration can serve as an adjunct treatment for social impairments in schizophrenia and other psychotic disorders. Aim 1: To quantify the effects of exogenous oxytocin on social cognition and behavior in patients with recent-onset schizophrenia. Hypothesis A: Patients and healthy comparison subjects will show enhanced social cognition (e.g., improved interpretation of paralinguistic and emotional cues, such as those involved in emotional or sarcastic communication) after administration of oxytocin versus placebo. Hypothesis B: Patients and healthy comparison subjects will show increased attention to others' eyes and patients will exhibit increased facial affect expressivity after administration of oxytocin versus placebo.
Interventions
- DRUG Oxytocin
- DRUG Saline Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2010-10 |
| Est. Completion | 2019-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02567032
The ClinicalTrials.gov registry entry for NCT02567032 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 324 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxytocin is the first listed.
NCT02567032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02567032 about?
NCT02567032 is a clinical study titled "Adult Study Oxytocin - Behavioral". In this study, investigators will examine the behavioral effects and neurophysiological mechanisms of the pro-social neuropeptide oxytocin in patients with recent-onset schizophrenia and other psychotic disorders. Such research is a necessary first step towards identifying whether intranasal oxytoci...
What is the current status of trial NCT02567032?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 324 participants. The study started on 2010-10. Estimated completion is 2019-08.
What interventions are being tested in trial NCT02567032?
The interventions under investigation include: Oxytocin (DRUG), Saline Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT02567032?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.